Name:
PARALLAX Study
Description:
PARALLAX Study
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/35836aad-2bad-42a5-bd1c-8228ac350e88/thumbnails/35836aad-2bad-42a5-bd1c-8228ac350e88.jpeg?sv=2019-02-02&sr=c&sig=P3HzRfMPg6yfBt7yBFh1sbE8qP7a7hOfb7Nv47vOB8s%3D&st=2024-12-21T17%3A03%3A52Z&se=2024-12-21T21%3A08%3A52Z&sp=r
Duration:
T00H03M25S
Embed URL:
https://stream.cadmore.media/player/35836aad-2bad-42a5-bd1c-8228ac350e88
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/35836aad-2bad-42a5-bd1c-8228ac350e88/18778962.mp3?sv=2019-02-02&sr=c&sig=CSqZNh5BL98b9kCOz3yeoT9cVczlSFE592VF9LgrydE%3D&st=2024-12-21T17%3A03%3A52Z&se=2024-12-21T19%3A08%3A52Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's, The Heart Board Review, and other online resources available only through accesscardiology.com. >> In the past, there have been numerous trials that noted a significant positive outcome in patients with heart failure and reduced ejection fraction with the agent Sacubitril/Valsartan. But can we see any similar result in patients with heart failure with preserved ejection fraction with this same agent?
[ Music ] Hi, Dr. Bernie, and welcome to Practice Impact Extra. The PARADIGM Heart Failure study published in 2016 noted an outcome benefit for patients treated with Sacubitril/Valsartan with reduced ejection fraction. Interesting within that group studied in PARADIGM were patients with an ejection fraction of greater than 45%.
This group results suggested a borderline benefit in responses to Sacubitril/Valsartan treatment, particularly noting decreased hospitalization. The PARALLAX study was presented at the European Society of Cardiology meeting in August 2020. At the Charite University Center in Berlin, 2,572 patients with heart failure and preserved ejection fraction, they have a mean ejection fraction of 56%, were randomized either to Sacubitril and Valsartan or optimal individual therapy.
So what were the results? They noted that the treated Sacubitril/Valsartan group showed a significant, 16% greater reduction in the NT-BNP at 12 weeks, although this effect seemed to lessen somewhat over time. They did not see any significant difference between the groups in terms of improvement in a six-minute walk distance at 24 weeks. Quality of life initially improved for both groups.
However, at 24 weeks, there was no difference in the groups. A post hoc analysis did suggest some less hospitalizations. So what do I think? I think the results of the PARALLAX studies were really not that impressive. I still remain frustrated that we cannot find a drug for this group of patients with preserved ejection fraction and heart failure. Research is suggesting that this may be the result of many potential underlying mechanisms operated here, including ischemia, fibrosis, hypertrophy, inflammation, and related vascular issues.
PARALLAX highlights the need for more studies to better identify phenotypes and newer, better therapeutic agents. Thank you again for joining me and see you next time on Practice Impact Extra. >> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to AccessCardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features. To subscribe or learn more, please visit accesscardiology.com.
